New Zealand parents and healthcare providers can breathe a sigh of relief following the publication of groundbreaking results from the University of Auckland-led PIPPA Tamariki trial. This landmark randomised controlled trial (RCT), the largest of its kind in the country, has confirmed that both paracetamol (also known as acetaminophen) and ibuprofen are safe for use in infants during their first year of life when administered as directed. Importantly, the study found no association between these common pain relievers and the development of eczema or bronchiolitis at age one.
Paracetamol and ibuprofen are the go-to medications for managing fever and pain in babies worldwide, including in New Zealand where they top the list of over-the-counter purchases for infants. Yet, lingering concerns from prior observational data had raised questions about potential long-term risks, particularly for respiratory and skin conditions. The PIPPA Tamariki study directly addresses these worries through rigorous scientific methodology, providing high-quality evidence that reassures families and clinicians alike.
🔬 The Genesis of the PIPPA Tamariki Trial
The Paracetamol and Ibuprofen in the Primary Prevention of Asthma in Tamariki (PIPPA Tamariki) trial emerged from a need to resolve inconsistencies in earlier research. Observational studies, such as the influential International Study of Asthma and Allergies in Childhood (ISAAC) phase three, reported associations between infant paracetamol use and increased odds of asthma (odds ratio [OR] 1.46, 95% confidence interval [CI] 1.36-1.56), rhinoconjunctivitis, and eczema. Systematic reviews echoed this, with pooled ORs around 1.5 for asthma risk, sparking debate over causality versus confounding factors like underlying infections prompting medication use.
Hypotheses for paracetamol's potential role included depletion of lung glutathione leading to oxidative stress and inflammation, or alteration of immune responses favoring T-helper type 2 (Th2) pathways linked to atopy. Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), lacks these proposed mechanisms, making it an ideal comparator. Launched in 2018, PIPPA Tamariki recruited nearly 4,000 infants across Auckland and Wellington—regions representing 43% of New Zealand's birth cohort—to test these links prospectively.
Under the leadership of Professor Stuart Dalziel, Cure Kids Chair of Child Health Research at the University of Auckland and paediatrician at Starship Children’s Hospital, alongside co-lead Dr. Eunicia Tan, the trial exemplifies New Zealand's prowess in paediatric research. Funded by the Health Research Council of New Zealand and Cure Kids, and conducted in partnership with the Medical Research Institute of New Zealand in Wellington, it underscores the vital role of university-led initiatives in advancing child health.
Study Design: Gold Standard Randomised Controlled Trial
PIPPA Tamariki is a multicentre, open-label, parallel-group RCT with 1:1 randomisation to paracetamol or ibuprofen arms. Eligible infants—born at ≥32 weeks gestation, under 8 weeks old at enrolment, residing in study regions—were assigned via computer-generated blocks stratified by site, maternal asthma, and multiple births. Parents provided only the allocated medication for fever or pain per New Zealand Formulary for Children guidelines: paracetamol 15 mg/kg every 6 hours (max 60 mg/kg/day), ibuprofen 5 mg/kg every 6-8 hours (max 20-30 mg/kg/day for <3 months, higher later).
Adherence was supported through mailed supplies, diaries, reminders, and pharmacy alerts. Follow-up involved parent questionnaires at 1, 3, 6, 9 months and 1, 3, 6 years, plus linkage to national health records for prescriptions, hospitalisations, and virology. Outcomes were assessed intention-to-treat using logistic regression with random effects, adjusting for confounders. The primary endpoint is asthma at age 6 (wheeze in past 12 months per ISAAC criteria), but first-year secondary outcomes—eczema and bronchiolitis hospitalisations—were prioritised for early publication in The Lancet Child & Adolescent Health.
This design minimises biases plaguing observational data, offering causal insights unattainable otherwise. Sample size powered for 90% detection of 23% relative asthma risk reduction (22% to 17%) at 6 years, accounting for 10-20% loss/adherence issues.
Key Findings: No Increased Risks Identified
Analysis of first-year data revealed no significant differences between groups. Eczema, parent-reported as itchy rash in past 12 months, affected 16% of paracetamol-assigned infants versus 15% in the ibuprofen group. Bronchiolitis, confirmed via hospital records or parent report of doctor-diagnosed severe lower respiratory infection, occurred in approximately 5% of both arms. Wheeze or asthma symptoms showed similarly negligible disparities.
- Eczema incidence: Paracetamol 16%, Ibuprofen 15% (non-significant)
- Bronchiolitis incidence: 5% in both groups
- Serious adverse events: Rare, none attributable to study drugs
These results dispel early concerns, affirming both medications' profiles for short-term use in healthy term infants. Dose-response analyses and multivariate adjustments further supported lack of association.
Safety Profile: Reassuring for Everyday Use
Safety was exemplary, with serious side effects exceedingly rare and unrelated to the interventions. Paracetamol, metabolised primarily in the liver via glucuronidation and sulfation (negligible CYP2E1 in neonates minimising toxicity), and ibuprofen, renally excreted with gastrointestinal precautions, aligned with known pharmacodynamics. No excess renal, hepatic, or allergic events emerged, validating dosing regimens from birth (ibuprofen from ~3 months per standard practice).
In New Zealand, where infant fever often stems from viral infections like respiratory syncytial virus (RSV), these drugs reduce discomfort without compromising immunity—fever suppression theories unproven here. Parents recorded usage diaries, averaging multiple doses during illnesses, mirroring real-world patterns.
Photo by Mufid Majnun on Unsplash
Expert Perspectives from University of Auckland Researchers
"Our study found that paracetamol and ibuprofen are incredibly safe to use in young children," states Professor Stuart Dalziel. "These results give parents and health professionals high confidence to continue to use these important medications." Dr. Eunicia Tan adds, "Ultimately, the study will provide important evidence regarding the link between paracetamol use and asthma, eczema, hay fever, and developmental disorders such as autism and ADHD."
Professor Dalziel's extensive portfolio in paediatric emergency medicine, including PREDICT network leadership, bolsters credibility. This trial highlights University of Auckland's Faculty of Medical and Health Sciences as a hub for impactful child health research, fostering collaborations that elevate New Zealand's global standing.Explore research positions at NZ universities
Implications for Parents and Healthcare Providers in New Zealand
For Kiwi families, this means confidently reaching for paracetamol drops for teething or mild fevers, or ibuprofen for post-immunisation soreness, per Paediatric Society of New Zealand endorsements. Step-by-step guidance:
- Assess need: Fever >38°C or discomfort unresponsive to non-pharmacologic measures (cuddles, fluids).
- Check age/weight: Paracetamol from birth (1 month+ routine), ibuprofen 3 months+.
- Dose accurately: Use syringe, not spoon; recalculate as baby grows.
- Monitor: Hydration, no alternation unless advised; seek GP if persistent fever >48 hours.
- Store safely: Child-proof, cool dark place.
General practitioners and pharmacists can cite this RCT to counter misinformation, aligning with Medsafe approvals. Cultural context: Māori and Pasifika communities, over-represented in asthma stats (NZ asthma prevalence ~20% children), benefit from evidence dispelling myths.Discover university opportunities in New Zealand
University of Auckland's Leadership in Paediatric Research
The PIPPA Tamariki trial showcases Waipapa Taumata Rau's (University of Auckland's te reo name) commitment to translational research. With Starship integration, it bridges academia and clinical care, attracting Health Research Council funding exceeding millions. Prof. Dalziel's 200+ publications and h-index reflect a vibrant ecosystem producing PhD talent and postdocs.View postdoc roles in higher ed
This positions UoA among Asia-Pacific leaders in RCTs, influencing policy via PHARMAC and WHO. For aspiring researchers, it's a gateway to careers in epidemiology, pharmacology, and public health.
Future Directions: Long-Term Follow-Up and Broader Impacts
Age 3 data forthcoming, with 6-year asthma verdict pivotal—transient wheeze resolves in two-thirds by school age. Secondary endpoints include atopy, hospitalisations, and neurodevelopmental links. Global implications: Challenges paracetamol hypotheses, potentially reshaping guidelines in Australia, UK (NHS), US (AAP).
In NZ higher ed, it signals funding for similar trials, boosting academic CVs via publications. Challenges: Adherence (10% dilution), open-label bias mitigated by objective records.
Stakeholder Views and Real-World Case Studies
Paediatricians applaud: NZ Doctor reports clinician relief. Parent forums echo gratitude, one Auckland mother sharing, "Feared paracetamol after online scares; now dosing confidently." Case: Hypothetical based on trial—3-month-old with RSV fever treated per arm, no eczema by year-end.
Stakeholders: Cure Kids praises impact; pharma neutral as generics. Multi-perspective: Critics note short-term only, but RCT superiority undisputed.
Photo by Maskmedicare Shop on Unsplash
Actionable Insights and Career Opportunities in Research
Parents: Consult PlunketLine (0800 933 922). Researchers: Join PREDICT for trials. UoA's ecosystem offers lecturer jobs in paediatrics, RA positions.
Optimism prevails: This trial heralds safer infancy, powered by NZ academia. Stay tuned for age-6 results.
In summary, PIPPA Tamariki debunks fears, affirming safety. Explore Rate My Professor, higher ed jobs, career advice, university jobs, or post a job at AcademicJobs.com.